Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the ...
The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...
Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...
Ascentage Pharma receives US FDA’s IND clearance for BTK degrader APG-3288 to treat patients with relapsed/refractory B-cell malignancies: Rockville, Maryland Friday, January 9, ...
Michael Wang, MD, highlights several notable abstracts from ASH 2025 that collectively underscore continued progress in ...
Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, ...
Heavy Spoilers on MSN
Mindhunter: Season 2 ending explained breakdown | Spoiler review, real life case & Season 3 BTK
| Spoiler Review, Real Life Case & Season 3 BTK by Deffinition, Episode 9 analysis, Netflix, BTK, Charles Manson, Son Of Sam, ...
Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the co ...
In late December 2025, Sanofi secured European Commission approval for Wayrilz (rilzabrutinib), the first BTK inhibitor for ...
New evidence for treatment of pulmonary embolism, asymptomatic carotid stenosis, and CLTI led the way in 2025.
Multiple sclerosis (MS) is a chronic autoimmune disease in which the immune system attacks the body’s nerves. Immune cells ...
Glioblastoma (GBM), the most common malignant brain tumor, remains difficult to treat because cancer stem cells (CSCs) drive resistance and recurrence. Although the Bruton tyrosine kinase (BTK) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback